Evotec

Last updated

Evotec SE
Company type Public
FWB:  EVT
FWB:  EVTA (ADR)
WBAG:  EVT
Nasdaq:  EVO (ADR)
MDAX component (FWB: EVT)
ISIN DE0005664809
US30050E1055
Industry Biotechnology, contract research organization
Founded1993;31 years ago (1993)
Founder Manfred Eigen
Headquarters Hamburg, Germany
Key people
  • Dr. Christian Wojczewski (CEO)
  • Iris Löw-Friedrich (chairwoman of the Supervisory Board)
Revenue618 million € (2021) [1]
Number of employees
>4,200 (2021) [1]
Website evotec.com

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion [2] and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. [3]

Contents

The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology (e.g. Alzheimer's disease, Huntington's disease), metabolic diseases (e.g. Diabetes), Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, [4] Bayer, [5] Sanofi, [6] Boehringer Ingelheim, [7] the CHDI Foundation, [8] Lilly, [9] Takeda, [10] Sernova, [11] and more.

On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. [12] On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. [13] The MDAX tracks 60 Prime Standard shares from sectors excluding technology. [14] On 8 November 2021, Evotec completed its secondary listing on the U.S. Nasdaq stock exchange on November 8 and raised $500 million. [15]

Company formation

Evotec SE was established as Evotec BioSystems GmbH in 1993 by a group of founders that included Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Schulte, Rudolf Rigler, Charles Weissmann and Nobel Laureate Manfred Eigen. [16] Eigen won the 1967 Nobel Prize in Chemistry for his work measuring ultrafast chemical reactions. [17]

Evotec Biosystems went public in 1999, listing on the Frankfurt Stock Exchange under the ticker symbol EVT. The following year, it merged with the British chemical services company Oxford Asymmetry International plc, [18] adopting the new name Evotec OAI.

In 2002, the company was divided into two business divisions; "Discovery and Development Services" and "Tools and Technologies," creating the wholly owned subsidiary Evotec Technologies GmbH. Four years later, this division was sold to PerkinElmer [19] in a move that, according to Evotec, allowed it to focus its resources towards the discovery and development of new pharmaceutical drugs. The company later rebranded as Evotec AG in 2005, with an aim to "reflect the growing emphasis of proprietary drug development in its business model and have a single "new" name which stands for both parts of its business." [20]

Notable acquisitions

In 2008, Evotec acquired US-based Renovis in a $152 million stock deal, [21] allowing it to list on the Nasdaq stock exchange. One year later, the company announced it was voluntarily de-listing its American Depositary Receipt to cut costs and concentrate its share trading on the German TecDAX platform. [22]

In 2010, the company acquired DeveloGen AG, [23] a spin-out from the Max Planck Institute for Biophysical Chemistry that was developing novel therapies for metabolic disorders, such as diabetes.

In 2011, Evotec acquired Kinaxo Biotechnologies GmbH, [24] a Munich-based, privately owned biotech company. Kinaxo specialized in chemical proteomics and its application in small molecule drug discovery. That same year, Evotec took control of Compound Focus [25] the compound management arm of the Galapagos group subsidiary Biofocus .

In January 2013, Evotec acquired CCS Cell Culture Service GmbH, [26] a Hamburg-based company that supplied custom cells and cell-based reagents for drug discovery applications.

In May 2014, Evotec acquired Euprotec for $3.15 million, [27] a contract research organization (CRO) with expertise in infectious diseases and respiratory biology.

In December 2016, Evotec completed its acquisition of Cyprotex, a preclinical contract research organization. [28]

In July 2017, Evotec acquired the integrated drug development services provider Aptuit for €256 million. [29]

In recent years, Evotec has made two significant deals with French pharmaceutical company Sanofi. In 2015, Evotec took over Sanofi's small-molecule drug development site in Toulouse, France, bringing approximately 200 Sanofi chemists into its team. [30] In 2018, Evotec acquired Sanofi's infectious disease unit, absorbing an additional 100 Sanofi employees and a majority of its anti-infectives research portfolio, including more than 10 R&D assets. [31] Per the agreement, Evotec will continue to run infectious disease R&D operations in Lyon, France. Evotec's initial focus will be on antimicrobial resistance ("AMR") and superbug infections, tuberculosis, and malaria, as well as the creation of novel antiviral therapies with new mechanisms of action.

In April 2019, Evotec AG announced it had completed its conversion into a company under European law (Societas Europaea, "SE"). It officially adopted the legal name Evotec SE, with its registration in the commercial register of the District Court of Hamburg. [32]

In May 2020, the company announced its acquisition of Just Biologics, a U.S.-based biologics company previously backed by the Gates Foundation. [33]

In June 2020, Evotec and two investment partners – Samsara BioCapital and KCK Ltd. – announced the launch of Autobahn Labs, a virtual incubator for early-stage research programs, headquartered in Palo Alto, California. [34]

In May 2022, Evotec announced the company are set to acquire Italy-based cell technology firm Rigenerand. The deal worth $24.5 million will include Evotec EVOcells cell therapy platform to Rigenerand's cGMP. [35]

Related Research Articles

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development presently known as Fortrea is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is spin-off from Labcorp, which employs more than 70,000 people worldwide.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

Altana AG is a German chemical company headquartered in Wesel. It was created in 1977, as a result of spinning off divisions from the Varta Group. The first CEO was Herbert Quandt.

Sigma-Aldrich is an American chemical, life science, and biotechnology company owned by the multinational chemical conglomerate Merck Group

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

<span class="mw-page-title-main">ViroPharma</span> American pharmaceutical company

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.

<span class="mw-page-title-main">Lonza Group</span> Swiss pharmaceutical and biotech company

Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

<span class="mw-page-title-main">Biotie Therapies</span> Finnish pharmaceutical company

Biotie Therapies Oyj was a Finnish biotechnology and pharmaceutics company that was acquired by Acorda Therapeutics in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki.

Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates. It was founded in 1979 by Rolland-Yves Mauvernay.

BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and from 2000 to 2023 on the Italian Borsa Italiana. The company invests mainly in the United States and Western Europe and is managed by Bellevue Asset Management, a division of Bellevue Group which accounts for approximately 40% of the Group's assets under management.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Curia is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. Curia has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Company, Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta, Pfizer and Novo Nordisk. The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018.

<span class="mw-page-title-main">Hanmi Pharm</span> South Korean pharmaceutical company

Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul.

<span class="mw-page-title-main">Cheplapharm Arzneimittel</span>

Cheplapharm Arzneimittel GmbH, headquartered in Greifswald, is a German pharmaceutical company that markets branded drugs, medical products, supplements and cosmetics.

Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley.

References

  1. 1 2 "Evotec 2021 Annual Report" (PDF). evotec. Retrieved 12 April 2022.
  2. ↑ "Evotec 2021 Annual Report" (PDF). evotec.com. Retrieved 12 April 2022.
  3. ↑ "Evotec 2021 Annual Report" (PDF). evotec. Retrieved 12 April 2022.
  4. ↑ "Evotec, Celgene Partner on Targeted Protein Degradation for Drug Discovery". GenomeWeb. Retrieved 5 December 2018.
  5. ↑ "Bayer and Evotec Extend their Endometriosis Partnership". labiotech.eu. 24 July 2017. Retrieved 5 December 2018.
  6. ↑ "Sanofi, Evotec in major infectious disease R&D transfer and license deal". FierceBiotech. Retrieved 24 November 2018.
  7. ↑ "Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology". Evotec. Retrieved 25 January 2022.
  8. ↑ "Evotec and CDHI form Huntington Disease alliance". Outsourcing-Pharma. Retrieved 24 November 2018.
  9. ↑ "Evotec and Lilly enter into drug discovery collaboration in metabolic diseases". Evotec. Retrieved 18 January 2022.
  10. ↑ "Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance". Evotec. Retrieved 22 March 2021.
  11. ↑ "Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes". bionity. Retrieved 19 May 2022.
  12. ↑ "Evotec Share". Boerse Frankfurt. Retrieved 13 December 2018.
  13. ↑ "Evotec AG listed in MDAX".
  14. ↑ "MDAX". Deutsche Boerse. Retrieved 13 December 2018.
  15. ↑ "Evotec completed US IPO". Deutsche Boerse Cash Market. Retrieved 9 November 2021.
  16. ↑ Jackle H, Rotte C, & Gruss P (2017) Manfred Eigen: the realization of his vision of Biophysical Chemistry. European biophysics journal Vol. 47, pp. 319-323.
  17. ↑ "Manfred Eigen". Max Planck Institute for Biophysical Chemistry. Archived from the original on 25 March 2019. Retrieved 13 December 2018.
  18. ↑ "Oxford Asymmetry agrees to German merger worth £316m". Independent.co.uk. 31 July 2000.
  19. ↑ "PerkinElmer buys Evotec Technologies". in-PharmaTechnologist. Retrieved 13 November 2018.
  20. ↑ "Evotec Ag (EVT:Xetra)". Bloomberg. Retrieved 13 December 2018.
  21. ↑ "Evotec Plans Acquisition Of Renovis In $152M Stock Deal". BioWorld.
  22. ↑ "Evotec To Voluntarily Delist American Depositary Shares From NASDAQ – Quick Facts". RTTNews. Retrieved 5 December 2018.
  23. ↑ "Evotec acquires metabolic diseases specialist DeveloGen for €14M". sciencebusiness.net.
  24. ↑ "Evotec Completes Acquisition of Kinaxo Biotechnologies GmbH". Technology Networks. Retrieved 5 December 2018.
  25. ↑ "Evotec acquires compound management business". Manufacturing Chemist. Retrieved 5 December 2018.
  26. ↑ "Evotec acquires Cell Culture Service for €1.2m in cash". Manufacturing Chemist. Retrieved 5 December 2018.
  27. ↑ "Evotec Buys Euprotec for Up to $3.15M". Genetic Engineering & Biotechnology News. 28 May 2014.
  28. ↑ "Evotec completes Cyprotex acquisition". Outsourcing-Pharma.
  29. ↑ "Aptuit sold for $300 million". Chemical & Engineering News.
  30. ↑ "Sanofi to send more researchers to Evotec – March 12, 2018 Issue – Vol. 96 Issue 11". Chemical & Engineering News.
  31. ↑ "Sanofi Agrees to Transfer Infectious Disease Unit, 100 Employees to Evotec". Genetic Engineering & Biotechnology News. 18 June 2018.
  32. ↑ "Evotec AG completes conversion into Evotec SE". Evotec.com.
  33. ↑ https://www.biopharma-reporter.com/Article/2019/05/29/Evotec-acquires-Just-Biotherapeutics-for-90m [ bare URL ]
  34. ↑ "Evotec, Samsara BioCapital, and KCK Launch Autobahn Labs". Contract Pharma. 24 June 2020. Retrieved 5 July 2020.
  35. ↑ "Evotec to acquire cell technology firm Rigenerand". Pharmaceutical Technology. 31 May 2022. Retrieved 26 May 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.